Literature DB >> 3953269

Antibodies to staphylococcal teichoic acid and alpha toxin in patients with cystic fibrosis.

A Ericsson, M Granström, R Möllby, B Strandvik.   

Abstract

Enzyme-linked immunosorbent assay (ELISA) was used for IgG antibody determination to teichoic acid and alpha-toxin from Staphylococcus aureus in 65 patients with cystic fibrosis (CF). In patients chronically colonized with S. aureus, elevated titres to teichoic acid were found in 13/35 (37%) patients, to alpha-toxin in 12/35 (34%) and to either antigen in 18/35 (51%). Patients with elevated titres to teichoic acid had a significantly lower X-ray score than patients with normal titres. The highest titres against both teichoic acid and alpha-toxin were seen in patients not receiving optimal treatment. These findings suggest that staphylococci contribute to the tissue damage in CF and that the determination of antibodies especially to staphylococcal teichoic acid might be of value in the diagnosis and management of staphylococcal infections in patients with CF.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3953269     DOI: 10.1111/j.1651-2227.1986.tb10170.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  11 in total

Review 1.  Cystic fibrosis. Infection and immunity to Staphylococcus aureus and Haemophilus influenzae.

Authors:  D P Greenberg; H R Stutman
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

2.  Prospective study of serum staphylococcal antibodies in cystic fibrosis.

Authors:  A E Hollsing; M Granström; B Strandvik
Journal:  Arch Dis Child       Date:  1987-09       Impact factor: 3.791

3.  Direct quantitative transcript analysis of the agr regulon of Staphylococcus aureus during human infection in comparison to the expression profile in vitro.

Authors:  C Goerke; S Campana; M G Bayer; G Döring; K Botzenhart; C Wolz
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

4.  Characterization of Staphylococcus aureus isolates from pediatric patients with cystic fibrosis.

Authors:  Ying Liu; Jiang Zhang; Dengke Zhong; Lu Ji; Junshu Yang; James Phillips; Yinduo Ji
Journal:  World J Microbiol Biotechnol       Date:  2016-08-25       Impact factor: 3.312

5.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

Review 6.  Cystic fibrosis. 2. Lung injury in cystic fibrosis.

Authors:  J S Elborn; D J Shale
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

Review 7.  Alpha-toxin of Staphylococcus aureus.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Microbiol Rev       Date:  1991-12

8.  Evaluation of new enzyme-linked immunosorbent assay based on a supernatant containing Staphylococcus aureus alpha-toxin produced by Bacillus subtilis.

Authors:  P Egnell; B Christensson; R Möllby; J I Flock
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

9.  Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis.

Authors:  A Albus; J M Fournier; C Wolz; A Boutonnier; M Ranke; N Høiby; H Hochkeppel; G Döring
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

10.  Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis.

Authors:  Ashley D Chadha; Isaac P Thomsen; Natalia Jimenez-Truque; Nicole R Soper; Lauren S Jones; Andrew G Sokolow; Victor J Torres; C Buddy Creech
Journal:  J Cyst Fibros       Date:  2016-01-25       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.